Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Multiple sclerosis and the risk of systemic venous thrombosis: A systematic review.

Ahmed O, Geraldes R, DeLuca GC, Palace J.

Mult Scler Relat Disord. 2019 Jan;27:424-430. doi: 10.1016/j.msard.2018.10.008. Epub 2018 Oct 17. Review. No abstract available.

PMID:
30642566
2.

Brain and cord imaging features in neuromyelitis optica spectrum disorders.

Cacciaguerra L, Meani A, Mesaros S, Radaelli M, Palace J, Dujmovic-Basuroski I, Pagani E, Martinelli V, Matthews L, Drulovic J, Leite MI, Comi G, Filippi M, Rocca MA.

Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411. [Epub ahead of print]

PMID:
30635936
3.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

PMID:
30587516
4.

Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Mealy MA, Mossburg SE, Kim SH, Messina S, Borisow N, Lopez-Gonzalez R, Ospina JP, Scheel M, Yeshokumar AK, Awad A, Leite MI, Arango JJ, Paul F, Palace J, Kim HJ, Levy M.

Mult Scler Relat Disord. 2018 Dec 9;28:64-68. doi: 10.1016/j.msard.2018.12.011. [Epub ahead of print]

PMID:
30554040
5.

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.

Juryńczyk M, Jacob A, Fujihara K, Palace J.

Pract Neurol. 2018 Dec 8. pii: practneurol-2017-001787. doi: 10.1136/practneurol-2017-001787. [Epub ahead of print]

PMID:
30530724
6.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

PMID:
30366977
7.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
8.

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD.

Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.

Neurology. 2018 Oct 23;91(17):e1642-e1651. doi: 10.1212/WNL.0000000000006392. Epub 2018 Sep 26.

9.

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Lilford R, Dobson C.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. doi: 10.1136/jnnp-2018-318360. Epub 2018 Sep 21.

10.

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study.

Oertel FC, Havla J, Roca-Fernández A, Lizak N, Zimmermann H, Motamedi S, Borisow N, White OB, Bellmann-Strobl J, Albrecht P, Ruprecht K, Jarius S, Palace J, Leite MI, Kuempfel T, Paul F, Brandt AU.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259-1265. doi: 10.1136/jnnp-2018-318382. Epub 2018 Jun 19.

PMID:
29921610
11.

The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes.

Rodríguez Cruz PM, Palace J, Beeson D.

Int J Mol Sci. 2018 Jun 5;19(6). pii: E1677. doi: 10.3390/ijms19061677. Review.

12.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

13.

Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M; MAGNIMS Study Group.

Radiology. 2018 Aug;288(2):554-564. doi: 10.1148/radiol.2018172468. Epub 2018 May 1.

PMID:
29714673
14.

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder.

Hacohen Y, Palace J.

Neurology. 2018 May 22;90(21):947-948. doi: 10.1212/WNL.0000000000005619. Epub 2018 Apr 25. No abstract available.

PMID:
29695599
15.

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4. No abstract available.

16.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337
17.

A practical approach to the diagnosis of spinal cord lesions.

Mariano R, Flanagan EP, Weinshenker BG, Palace J.

Pract Neurol. 2018 Jun;18(3):187-200. doi: 10.1136/practneurol-2017-001845. Epub 2018 Mar 2. Review.

PMID:
29500319
18.

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.

De Stefano N, Giorgio A, Tintoré M, Pia Amato M, Kappos L, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group.

Mult Scler. 2018 Feb;24(2):214-221. doi: 10.1177/1352458517717808. No abstract available.

PMID:
29451440
19.

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.

Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J, Woodhall M, Palace J, Leite MI, Waters P, Irani SR.

Brain. 2018 Apr 1;141(4):1063-1074. doi: 10.1093/brain/awy010.

20.

A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS).

Coe S, Collett J, Izadi H, Wade DT, Clegg M, Harrison JM, Buckingham E, Cavey A, DeLuca GC, Palace J, Dawes H.

Pilot Feasibility Stud. 2018 Jan 23;4:35. doi: 10.1186/s40814-018-0230-7. eCollection 2018.

21.

Therapeutic strategies for congenital myasthenic syndromes.

Lee M, Beeson D, Palace J.

Ann N Y Acad Sci. 2018 Jan;1412(1):129-136. doi: 10.1111/nyas.13538. Review.

PMID:
29381222
22.

Serological and experimental studies in different forms of myasthenia gravis.

Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez-Cruz P, Jacobson L, Viegas S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R, Palace J, Beeson D.

Ann N Y Acad Sci. 2018 Feb;1413(1):143-153. doi: 10.1111/nyas.13592. Epub 2018 Jan 29. Review. Erratum in: Ann N Y Acad Sci. 2018 Apr;1417(1):130.

PMID:
29377162
23.

Myasthenic syndromes due to defects in COL13A1 and in the N-linked glycosylation pathway.

Beeson D, Cossins J, Rodriguez-Cruz P, Maxwell S, Liu WW, Palace J.

Ann N Y Acad Sci. 2018 Feb;1413(1):163-169. doi: 10.1111/nyas.13576. Epub 2018 Jan 24. Erratum in: Ann N Y Acad Sci. 2018 Apr;1417(1):131.

PMID:
29363764
24.

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostásy K, Neuteboom R, Deiva K, Lim M.

JAMA Neurol. 2018 Apr 1;75(4):478-487. doi: 10.1001/jamaneurol.2017.4601.

25.

Atypical periodic paralysis and myalgia: A novel RYR1 phenotype.

Matthews E, Neuwirth C, Jaffer F, Scalco RS, Fialho D, Parton M, Raja Rayan D, Suetterlin K, Sud R, Spiegel R, Mein R, Houlden H, Schaefer A, Healy E, Palace J, Quinlivan R, Treves S, Holton JL, Jungbluth H, Hanna MG.

Neurology. 2018 Jan 30;90(5):e412-e418. doi: 10.1212/WNL.0000000000004894. Epub 2018 Jan 3.

26.

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Jurynczyk M, Probert F, Yeo T, Tackley G, Claridge TDW, Cavey A, Woodhall MR, Arora S, Winkler T, Schiffer E, Vincent A, DeLuca G, Sibson NR, Isabel Leite M, Waters P, Anthony DC, Palace J.

Acta Neuropathol Commun. 2017 Dec 6;5(1):95. doi: 10.1186/s40478-017-0495-8.

27.

Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.

McKee JB, Cottriall CL, Elston J, Epps S, Evangelou N, Gerry S, Kennard C, Kong Y, Koelewyn A, Kueker W, Leite MI, Palace J, Craner M.

Mult Scler. 2017 Nov 1:1352458517742979. doi: 10.1177/1352458517742979. [Epub ahead of print]

PMID:
29172994
28.

Clinical presentation and prognosis in MOG-antibody disease: a UK study.

Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J.

Brain. 2017 Dec 1;140(12):3128-3138. doi: 10.1093/brain/awx276. No abstract available.

PMID:
29136091
29.

A mathematical model of cellular swelling in Neuromyelitis optica.

Laranjeira S, Symmonds M, Palace J, Payne SJ, Orlowski P.

J Theor Biol. 2017 Nov 21;433:39-48. doi: 10.1016/j.jtbi.2017.08.020. Epub 2017 Aug 23.

PMID:
28843390
30.

Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.

Hacohen Y, Messina S, Gan HW, Wright S, Chandratre S, Leite MI, Fallon P, Vincent A, Ciccarelli O, Wassmer E, Lim M, Palace J, Hemingway C.

Mult Scler. 2018 Apr;24(5):679-684. doi: 10.1177/1352458517726593. Epub 2017 Aug 14.

PMID:
28803524
31.

Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder.

Combes AJE, Matthews L, Lee JS, Li DKB, Carruthers R, Traboulsee AL, Barker GJ, Palace J, Kolind S.

Neuroimage Clin. 2017 Jun 16;16:17-22. doi: 10.1016/j.nicl.2017.06.019. eCollection 2017.

32.

Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.

Yates RL, Esiri MM, Palace J, Jacobs B, Perera R, DeLuca GC.

Ann Neurol. 2017 Aug;82(2):259-270. doi: 10.1002/ana.24997. Epub 2017 Aug 19.

PMID:
28719020
33.

Differential diagnosis of neuromyelitis optica spectrum disorders.

Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K.

Ther Adv Neurol Disord. 2017 Jul;10(7):265-289. doi: 10.1177/1756285617709723. Epub 2017 May 24. Review.

34.

A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).

Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, Howe R, Holland R, Kelly J, McCrone P, Murphy C, Palace J, Pickles A, Pike M, Robertson N, Jacob A, Lim M.

Health Technol Assess. 2017 May;21(31):1-50. doi: 10.3310/hta21310.

35.

Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.

Sisay S, Lopez-Lozano L, Mickunas M, Quiroga-Fernández A, Palace J, Warnes G, Alvarez-Lafuente R, Dua P, Meier UC.

J Neuroimmunol. 2017 May 15;306:40-45. doi: 10.1016/j.jneuroim.2017.02.017. Epub 2017 Mar 2.

PMID:
28385186
36.

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, DeLuca G, Chandratre S, Leite MI, Vincent A, Palace J.

Brain. 2017 Mar 1;140(3):617-627. doi: 10.1093/brain/aww350.

PMID:
28364548
37.

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. doi: 10.1136/jnnp-2016-314005. Epub 2016 Oct 8.

PMID:
27951522
38.

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.

Tackley G, Vecchio D, Hamid S, Jurynczyk M, Kong Y, Gore R, Mutch K, Woodhall M, Waters P, Vincent A, Leite MI, Tracey I, Jacob A, Palace J.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):165-169. doi: 10.1136/jnnp-2016-314991. Epub 2016 Nov 24.

PMID:
27884934
39.

Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

Geraldes R, Esiri MM, DeLuca GC, Palace J.

Brain Pathol. 2017 Nov;27(6):707-722. doi: 10.1111/bpa.12460. Epub 2017 Mar 12. Review.

PMID:
27864848
40.

Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.

Kong Y, Okoruwa H, Revis J, Tackley G, Leite MI, Lee M, Tracey I, Palace J.

J Neurol Sci. 2016 Sep 15;368:84-8. doi: 10.1016/j.jns.2016.06.041. Epub 2016 Jun 23.

PMID:
27538606
41.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954
42.

The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M.

Mult Scler. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739. Review.

PMID:
27465613
43.

Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom.

Rodríguez Cruz PM, Matthews L, Boggild M, Cavey A, Constantinescu CS, Evangelou N, Giovannoni G, Gray O, Hawkins S, Nicholas R, Oppenheimer M, Robertson N, Zajicek J, Rothwell PM, Palace J.

JAMA Neurol. 2016 Aug 1;73(8):954-60. doi: 10.1001/jamaneurol.2016.1463.

PMID:
27366989
44.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

45.

Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment.

Tackley G, O'Brien F, Rocha J, Woodhall M, Waters P, Chandratre S, Halfpenny C, Hemingway C, Wassmer E, Wasiewski W, Leite MI, Palace J.

Mult Scler Relat Disord. 2016 May;7:21-5. doi: 10.1016/j.msard.2016.02.014. Epub 2016 Feb 16.

PMID:
27237752
46.

Chronic pain disrupts the reward circuitry in multiple sclerosis.

Seixas D, Palace J, Tracey I.

Eur J Neurosci. 2016 Aug;44(3):1928-34. doi: 10.1111/ejn.13272. Epub 2016 Jun 10.

PMID:
27178661
47.

Clinical features of the myasthenic syndrome arising from mutations in GMPPB.

Rodríguez Cruz PM, Belaya K, Basiri K, Sedghi M, Farrugia ME, Holton JL, Liu WW, Maxwell S, Petty R, Walls TJ, Kennett R, Pitt M, Sarkozy A, Parton M, Lochmüller H, Muntoni F, Palace J, Beeson D.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):802-9. doi: 10.1136/jnnp-2016-313163. Epub 2016 May 4.

48.

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. Epub 2016 Apr 25.

49.

Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment.

Pittock SJ, Palace J.

Handb Clin Neurol. 2016;133:165-83. doi: 10.1016/B978-0-444-63432-0.00010-4.

PMID:
27112677
50.

Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.

Huda S, Cavey A, Izat A, Mattison P, Boggild M, Palace J.

J Neurol Sci. 2016 Mar 15;362:66-8. doi: 10.1016/j.jns.2016.01.011. Epub 2016 Jan 6.

PMID:
26944120

Supplemental Content

Loading ...
Support Center